Study type: In vitro · Status: Verified against declared source

Use of ceragenins as a potential treatment for urinary tract infections.

BMC infectious diseases · 2019

Study scale: The killing activity of LL-37, doxycycline, ceragenins CSA-13 and CSA-131 and combinations of LL-37 with doxycycline, CSA-13 and CSA-131 were determined against four E.

Abstract only: Open source record

Product or molecular entity relationships

  • LL-37: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Human bladder epithelial cell line T24 (ATCC® HTB­4™), purchased from American Type Culture Collection (ATCC), was cultured at 37 °C with 5% CO2 in McCoy’s 5A medium (ATCC, catalog no.

Methods

Among other factors explaining failure of antibiotic therapy of UTIs is ineffective eradication of intracellular pathogens that might avoid antibiotic therapy and host immune response when after uptake are hiding as intracellular microorganism in cytosol of epithelial cells [11, 12].

Scale or participants

The killing activity of LL-37, doxycycline, ceragenins CSA-13 and CSA-131 and combinations of LL-37 with doxycycline, CSA-13 and CSA-131 were determined against four E.

Key findings

Urinary tract infections (UTIs) are one of the most common bacterial infections.

Limitations and uncertainty

To date, it was found that biofilm resistance to antimicrobial agents is determined by poor penetration and reduced diffusion of antibiotics into the biofilm, nutrient limitation, the presence of persister cells, slow growth rates or increased horizontal transfer of resistance genes [51, 52].

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.